

1 Comparative performance of SARS CoV-2 lateral flow antigen tests 2 demonstrates their utility for high sensitivity detection of infectious virus in 3 clinical specimens

4
5
6 Suzanne Pickering¹, Rahul Batra², Luke B. Snell², Blair Merrick², Gaia Nebbia², Sam
7 Douthwaite², Amita Patel², Mark Tan Kia Ik², Bindi Patel², Themoula Charalampous², Adela
8 Alcolea-Medina^{2,3}, Maria Jose Lista¹, Penelope R. Cliff³, Emma Cunningham³, Jane Mullen³,
9 Katie J. Doores¹, Jonathan D. Edgeworth^{1,2}, Michael H. Malim¹, Stuart J.D. Neil^{1*}, Rui Pedro
10 Galão^{1*}

11
12 ¹ Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's
13 College London, London SE1 9RT, UK

14
15 ² Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases,
16 Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH

17
18 ³ Viapath Group LLP, Guy's and St Thomas' NHS Foundation Trust, London, UK

19
20
21 * Joint corresponding authors

22 Rui Pedro Galão ruip.pedro.galao@kcl.ac.uk
23 +44 207 848 2610

24
25 Stuart J.D. Neil stuart.neil@kcl.ac.uk
26 +44 207 848 9617

27 28 Abstract

29
30 **Background:** Rapid antigen lateral flow devices (LFDs) are set to become a cornerstone of
31 SARS-CoV-2 mass community testing. However, their reduced sensitivity compared to PCR
32 has raised questions of how well they identify infectious cases. Understanding their capabilities
33 and limitations is therefore essential for successful implementation. To address this, we
34 evaluated six commercial LFDs on the same collection of clinical samples and assessed their
35 correlation with infectious virus culture and cycle threshold (Ct) values.

36
37 **Methods:** A head-to-head comparison of specificities and sensitivities was performed on six
38 commercial rapid antigen tests using combined nasal/oropharyngeal swabs, and their limits of
39 detection determined using viral plaque forming units (PFU). Three of the LFDs were selected
40 for a further study, correlating antigen test result with RT-PCR Ct values and positive viral
41 culture in Vero-E6 cells. This included sequential swabs and matched serum samples obtained
42 from four infected individuals with varying disease severities. Detection of antibodies was
43 performed using an IgG/IgM Rapid Test Cassette, and neutralising antibodies by infectious
44 virus assay. Finally, the sensitivities of selected rapid antigen LFTs were assessed in swabs
45 with confirmed B.1.1.7 variant, currently the dominant genotype in the UK.

46
47 **Findings:** Most of the rapid antigen LFDs showed a high specificity (>98%), and accurately
48 detected 50 PFU/test (equivalent NI Ct of 23.7 or RNA copy number of 3x10⁶/ml).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

49 Sensitivities of the LFDs performed on clinical samples ranged from 65 to 89%. These
50 sensitivities increased in most tests to over 90% for samples with Cts lower than 25. Positive
51 virus culture was achieved for 57 out of 141 samples, with 80% of the positive cultures from
52 swabs with Cts lower than 23. Importantly, sensitivity of the LFDs increased to over 95% when
53 compared with the detection of infectious virus alone, irrespective of Ct. Longitudinal studies
54 of PCR-positive samples showed that most of the tests identified all infectious samples as
55 positive, but differences in test sensitivities can lead to missed cases in the absence of repeated
56 testing. Finally, test performance was not impacted when re-assessed against swabs positive
57 for the dominant UK variant B.1.1.7.

58

59 **Interpretation:** In this comprehensive comparison of antigen LFD and virus infectivity, we
60 demonstrate a clear relationship between Ct values, quantitative culture of infectious virus and
61 antigen LFD positivity in clinical samples. Our data support regular testing of target groups
62 using LFDs to supplement the current PCR testing capacity, to rapidly identify infected
63 individuals in situations where they would otherwise go undetected.

64

65 **Funding:** King's Together Rapid COVID-19, Medical Research Council, Wellcome Trust,
66 Huo Family Foundation.

67

68 Introduction

69

70 Covid-19 continues to have a profound impact on global health, with many countries resorting
71 to economically and socially damaging restrictions to minimise the spread of SARS-CoV-2
72 and protect healthcare systems from being overwhelmed.

73

74 Pathways out of national lockdowns - and strategies to mitigate the need for them in the future
75 – depend upon the successful implementation of mass vaccination programmes, effective
76 contact tracing systems and mass community testing. In addition to the existing PCR-based
77 testing systems, the latter may take the form of targeted intensive testing in increasing
78 incidence areas, alongside regular routine screening in healthcare, education, workplace and
79 leisure settings. Realistically, the expansion of mass regular testing relies heavily on an element
80 of low-infrastructure- or self-testing, such as that offered by rapid antigen lateral flow devices
81 (LFDs).^{1,2}

82

83 Thoroughly understanding the advantages and limitations of rapid antigen LFDs is, therefore,
84 a priority and will help to inform decisions about where these tests will have the most utility
85 and, conversely, where they could be contraindicated. There are concerns about their reduced
86 sensitivity in comparison to PCR, and controversies have arisen over the suitability of their
87 implementation.³⁻⁵ Problems with comparing Ct values from RT-qPCR between different
88 protocols, and even between the same protocols at different locations, combined with
89 uncertainty about the range of viral loads that constitute a transmission risk, have been the root
90 of many of the issues.^{5,6} Individuals are most infectious around the time of symptom onset,
91 when viral loads in the upper respiratory tract are highest,^{7,8} with recent studies confirming an
92 association between viral load and increased transmission of SARS-CoV-2.⁹ For asymptomatic
93 individuals, infectivity and viral load dynamics involve a similar, limited, period of infectivity,
94 and asymptomatic and pre-symptomatic contributions to spread in the community remain
95 problematic.^{10,11}

96

97 Several studies have shown a relationship between Ct value and virus infectivity,^{8, 12-14} and
98 manufacturers of rapid antigen LFDs have implied a link between antigen test positivity and
99 infectious potential. Here we present a detailed assessment of the relationship between Ct,
100 quantitative culture of infectious virus and antigen test positivity, alongside an independent
101 and unbiased head-to-head comparison of six widely available commercial antigen tests. Most
102 tests showed good sensitivity (>90%) at Cts of less than 25, with sensitivity increasing to over
103 95% when compared to infectious samples. Longitudinal studies of PCR-positive samples
104 highlight the importance of regular testing. We also re-assessed the tests against the dominant
105 genotype in the UK, B.1.1.7, and found no difference in test performance.

106

107

108 Materials and Methods

109

110 Study samples and ethics

111

112 Combined nasal/oropharyngeal swabs were submitted to the diagnostic laboratory in 1 ml of
113 viral transport medium (VTM) for routine real time SARS-CoV-2 RT-PCR testing. Surplus
114 VTM was routinely stored at -80°C by the diagnostic laboratory for future technology
115 evaluations. VTM from 100 laboratory-confirmed SARS-CoV-2 positive swabs selected to
116 cover a wide range of Cts (14 to 39) and 100 confirmed negative swabs were used for head-to-
117 head comparisons of 6 commercial antigen tests. Similarly, VTM from an additional 141
118 confirmed positive swabs were used for comparative studies on infectivity and antigen testing.
119 All samples were collected between March and October 2020. A further 23 laboratory-
120 confirmed SARS-CoV-2 positive swabs, collected in January 2021, were shown by on-site
121 whole-genome sequencing to be from the B.1.1.7 variant and used for comparative evaluation
122 of the sensitivity of selected tests.

123

124 Matched routinely-collected serum samples stored for up to 48 hours at 4°C in the Viapath
125 Blood Sciences laboratory were retrieved after routine diagnostic testing prior to planned
126 discard and stored at -80°C for future serological analysis. All swabs, VTM and serum samples
127 were stored in the Directorate of Infection. Samples for research were retrieved by the primary
128 care team and anonymised before sending to the King's College London laboratories for
129 analysis along with dates of symptom onset and sample collection, and any relevant routine
130 laboratory result obtained from that sample. All studies were performed in accordance with the
131 UK Policy Framework for Health and Social Care Research and with specific Research Ethics
132 Committee approval (REC 20/SC/0310).

133

134

135 Viral growth assays

136

137 For the comparative studies on infectivity and antigen positivity, each swab was subjected to
138 the following procedures: RNA extraction for subsequent RT-PCR and sequencing; titration
139 and viral titre determination by plaque assay; titration and infectivity determination by
140 intracellular anti-N staining; viral propagation for isolation of virus; and rapid antigen testing.
141 Viral growth assays were performed on Vero.E6 cells. For plaque assays, VTM was 10-fold
142 serially diluted and applied to Vero.E6 cells in 12-well plates, in a volume of 500 ul per well,
143 and incubated for 1 hour at 37°C. 500 ul of pre-warmed overlay (0.1% agarose in DMEM
144 supplemented with 2% FCS, pen/strep and amphotericin B) was then applied to each well, and
145 cultures were incubated for 72 hours at 37°C, before fixing with 4% formaldehyde. A solution
146 of 0.05% crystal violet in ethanol was applied to each well, incubated for 5 minutes at room
147 temperature, before washing with PBS, air drying and counting plaques.

148

149 RT-PCR

150

151 Initial diagnostic laboratory testing was carried using the AusDiagnostics Multiplex Tandem
152 SARS-CoV-2 PCR assays at Viapath Infection Sciences laboratory, St Thomas' Hospital,
153 London, and positive or negative swabs were selected on basis of this diagnostic test. For
154 additional PCR testing and to ensure uniformity of RT-PCR conditions and Ct determination,
155 RNA was extracted from 100ul of swab using the Qiagen QIAamp Viral RNA Kit following
156 manufacturer's instructions and eluted in 60ul of water. RT-PCR reactions (total volume 20µl)
157 were performed with 5µl of eluted RNA, 4x TaqMan Fast Virus 1-Step Master mix (Applied

158 Biosystems) and CDC's IDT Primer-Probes Sets targeting SARS-CoV-2 N gene regions or
159 human RNase P, using a QuantStudio 5 (ThermoFisher Scientific). RNA standards were
160 extracted as above from serial dilutions of a NATtrol™ SARS-CoV-2 Stock (ZeptoMetrix),
161 which is constituted of inactivated intact viral particles with known RNA viral load.

162

163 **Rapid antigen tests**

164

165 Tests were performed according to the manufacturers' instructions, with the exception that
166 swabs stored in viral transport medium (VTM) were used for evaluations, rather than direct
167 swabs performed immediately prior to test performance. 50 ul of stored swab was mixed with
168 100 ul of buffer supplied with the test kit, and 100 ul of this was applied to the test cassette.
169 Results were scored at the time stipulated by the manufacturer (between 10 and 30 minutes).
170 Results were recorded independently by two readers, compared, and in the event of a discordant
171 score were referred to a third individual. For the purpose of comparison, chromatographic tests
172 were scored according to whether the test band was strongly positive (2), clearly positive (1),
173 weakly positive (0.5) or negative (0).

174

Rapid Antigen LFD	Distributor/Manufacturer	Reference
SARS-CoV-2 Antigen Test Kit	Innova Med Group	N/A
SARS-CoV-2 Antigen Rapid Test Cassette (Swab)	Spring Healthcare	SP-SW 106
SARS-CoV-2 Antigen Rapid Test Cassette (Nasopharyngeal Swab)	SureScreen Diagnostics Ltd	COVID19 AGVCT
SARS-CoV-2 Antigen Rapid Test Device	Emmo Pharma / Encode	N/A
COVID-19 Antigen Rapid Fluorescent Cassette	SureScreen Diagnostics Ltd	COVID19 AGC
Rapid Diagnostic Test	E25Bio	N/A

175 **Table 1:** Rapid antigen LFD names and manufacturers

176

177 **Neutralisation assays**

178

179 Neutralisation assays were performed on Vero.E6 cells with replication-competent SARS-
180 CoV-2 (England 02/2020) as previously described.¹⁵ Briefly, 20,000 cells were seeded per well
181 of a 96-well plate the day before assay. Heat-inactivated sera were 3-fold serially diluted and
182 incubated with 400 PFU per well of SARS-CoV-2 for 1 hour at 37°C. Medium was removed
183 from the cells and replaced with the virus/serum mixtures. After 24 hours at 37°C, cells were
184 fixed in 4% formaldehyde before intracellular nucleocapsid staining.

185

186 **Intracellular nucleocapsid staining**

187

188 Immunostaining for SARS-CoV-2 nucleocapsid detection in Vero.E6 cells was performed *in*
189 *situ* in formaldehyde-fixed 96-well plates, to verify viral culture experiments and as a read-out
190 for infectious virus neutralisation assays, as described previously.¹⁵ Briefly, cells were
191 permeabilised with 0.1% triton in PBS for 15 minutes, then blocked in 3% milk for 15 minutes
192 at room temperature. Primary antibody (murinized anti-N 3009) was incubated at a final
193 concentration of 2 ug/mL in 1% milk for 45 minutes at room temperature, before washing twice
194 with PBS and incubating with secondary antibody (goat-anti-mouse IgG HRP-linked, Cell
195 Signaling Technology, 1:2000) in 1% milk for 45 minutes at room temperature. Cells were
196 washed twice with PBS, before addition of substrate. For SARS-CoV-2 plaque verification
197 assays, TrueBlue HRP substrate was used (Seracare Life Sciences Inc.); for neutralisation

198 assays, 1-Step Turbo TMB-ELISA substrate (ThermoFisher Scientific) was applied to the cells
199 before quenching with sulfuric acid and reading at 450 nm.

200

201 **Rapid antibody tests**

202

203 Presence of IgM and IgG antibodies in matched serums was assessed using the lateral flow
204 immunoassay (LFIA) COVID-19 IgG/IgM rapid test cassette (SureScreen). 10 µl of serum was
205 added to the LFIA membrane start point, followed by 2 drops of supplied buffer. Kits were run
206 at room temperature for 10 minutes and scored both IgM and IgG. Scoring (negative,
207 borderline, positive, strong positive) was performed independently by two individuals.

208

209 **Statistical Analyses**

210

211 Expected binomial exact 95% confidence intervals were calculated on Prism 8.0 using
212 Wilson/Brown statistical analysis. Significance of comparative sensitivities using swabs from
213 different time periods was determined by repeated measures ANOVA.

214

215 **Role of the funding source**

216

217 Funding sources had no involvement in the study design; in the collection, analysis, and
218 interpretation of the data; in the writing of the report; or in the decision to submit this
219 manuscript for publication.

220

221

222

223 Results

224

225 **Head-to-head comparison of specificities, sensitivities and limits of detection of** 226 **commercial rapid antigen tests**

227 Six commercial rapid antigen tests (Innova, E25 Bio, SureScreen visual (V), Spring, Encode
228 and SureScreen fluorescent (F); **Table 1**) were compared in specificity, limit-of-detection
229 (LOD) and sensitivity validations.

230

231 Comparative specificity was determined for each test using a panel of 100 SARS-CoV-2
232 negative swabs (**Table 2**). All tests demonstrated high (>98%) specificity, with the exception
233 of E25Bio. SureScreen and Encode achieved 100%. None of the negative samples gave false
234 positive results in more than one test, suggesting that false positives appear stochastically and
235 are not a particular feature of the samples. All false positives were only weakly positive, with
236 the exception of SureScreen F for which this information was not available as the electronic
237 reader delivers a binary result.

238

239 LODs were determined using specified plaque-forming units (PFU) of Vero.E6-propagated
240 SARS-CoV-2 (England 02/2020 strain). Serial dilutions of virus stock were applied to each
241 test in triplicate. Informed by the specificity determinations - in which there were very few
242 false positives - any visible band was considered positive regardless of intensity or relationship
243 to the control band. Although the tests are qualitative, results are displayed as a heatmap to
244 convey the magnitude of the result, allowing more detailed comparisons between the tests and
245 potentially informing future use. Most tests reliably detected 50 PFU per test (1500 PFU per
246 mL) with the exception of Encode and SureScreen F (**Figure 1A**). SureScreen V and Innova
247 had the lowest consistent LOD, and upon further testing SureScreen also consistently detected
248 20 PFU per test (600 PFU/mL; data not shown). Calibration experiments conducted on SARS-
249 CoV-2 laboratory stocks (**Figure 1B**) and standardised RNA control reagents (**Figure 1C**)
250 delivered the equivalent N1 Ct of 23.7 or RNA copy number of 3×10^6 /ml for the LOD of 1500
251 PFU per mL. As particle-to-infectious unit ratios can vary between viral variants or according
252 to growth or assaying conditions, as an additional control we applied the Zeptomatrix NATrol
253 inactivated viral particle standard to the two tests with the best LOD – Innova and SureScreen.
254 This was weakly positive on both tests at a copy number of 1.2×10^6 /ml (data not shown), or
255 projected Ct value of 25, in agreement with the results shown in **Figure 1**.

256

257 Sensitivity comparisons on clinical samples were performed as head-to-head evaluations on
258 100 PCR-confirmed SARS-CoV-2 combined nasal/oropharyngeal swabs with Cts ranging
259 from 14 to 39 (**Figure 1D**). Swabs were selected to cover a wide range of Cts, from 14 to 39.
260 Overall sensitivities are presented, as well as sensitivities determined for samples with a Ct less
261 than 25, corresponding to approximately 1.5×10^6 copies/ml or 400 PFU/ml, and Ct 28,
262 corresponding to a copy number of approximately 1.65×10^5 copies/ml or 50 PFU/ml. Innova
263 had the highest overall sensitivity (89%) using clinical samples, with this increasing to 96 and
264 99% when applied to samples with Cts of less than 28 and 25 respectively (**Table 2**). All other
265 tests had overall sensitivities of between 65 and 77%, increasing to over 90% for samples with
266 Cts of less than 25 for all tests except SureScreen F. Thus, there was good sensitivity and
267 specificity for all tests on swabs within a defined Ct window.

268

269 **Select LFDs predict swabs with infectious culturable SARS CoV-2 with very high** 270 **sensitivity**

271

272 Three of the rapid antigen tests from the first phase of comparisons were then selected for more
273 detailed comparisons: the test with highest sensitivity (Innova), highest specificity (Encode)
274 and a test with alternative technology (fluorescent machine-read result; SureScreen F). 141
275 combined nasal/oropharyngeal swabs were compared for N1 Ct value, antigen test result, and
276 positive viral culture (**Figure 2A**). Samples covered a range of Cts from 12.7 to 40. The direct
277 viral titre of the swabs was determined by plaque assay of serially diluted swabs, with
278 additional confirmatory intracellular anti-SARS-CoV-2 nucleocapsid staining performed on
279 viral culture samples for 110 of the 141 samples. 57 of the 141 samples were positive for viral
280 growth (40.4%). 80% of cultures yielded Cts of less than 23, and the highest Ct from a sample
281 with positive viral culture was 26.3. The latest time point that we were able to isolate virus
282 from was 15 days post onset of symptoms. Titres of infectious virus in the samples showed an
283 inverse linear relationship with N1 Ct values (**Figure 2B**). Both viral culture and antigen test
284 positivity were associated with Ct value, rather than the timing of the sample post onset of
285 symptoms (**Figure 2C**).

286
287 Overall antigen test sensitivities and rankings were similar to those seen in **Figure 1**, with
288 Innova delivering the highest sensitivity at 78%, then Encode (74%), followed by SureScreen
289 F (60%) (**Table 3**). When compared only to the samples from which virus was cultured, all
290 tests achieved a sensitivity of at least 95% (**Figure 2A** and **Table 4**). One point to note is that
291 due to sample volume or test availability, not all samples could be assayed on Innova and
292 Encode.

293
294 To investigate the change of antigen test result over time, sequential combined
295 nasal/oropharyngeal swabs were retrieved where available from 4 infected inpatients with
296 varying disease severities and compared for N1 Ct value, antigen test result (SureScreen F,
297 SureScreen V, Innova and Encode), and positive viral culture (**Figure 2D**). Matched serum
298 samples were also retrieved from the same individuals where routine testing had been
299 performed, and assayed for the appearance of antibodies (IgM and IgG by SureScreen COVID-
300 19 IgG/IgM Rapid Test Cassette), and neutralising antibodies by infectious virus assay). All
301 tests identified infectious samples as positive (with the exception of one sample by SureScreen
302 F), and continued to deliver positive results for several days after peak infectivity. In patients
303 2-4, Innova (and where available, Encode) tested positive for up to 8 days longer than
304 SureScreen F, although the exact length of this extended positivity cannot be stated as
305 intermediate samples were not obtained. In two cases, PCR testing identified pre-infectious
306 individuals (Patients 2 and 4) who were negative in all antigen tests. Two days later, a drop in
307 Ct value coincided with antigen test positivity for all tests and the isolation of infectious virus
308 in one of these individuals. Longitudinal results therefore highlight the importance of repeat,
309 rather than one-off, testing with rapid antigen LFDs.

310
311 In two individuals, the occurrence of neutralising antibodies coincided with a dip in antigen
312 test band strength (**Figure 2D**; patients 1 and 4). We also examined matched serum samples
313 from 76 of 141 samples shown in Figure 2A and found no relationship between antigen test
314 positivity, infectivity and the presence of antibodies (data not shown).

315 316 **Rapid antigen tests detect the B.1.1.7 variant with equivalent sensitivity**

317
318 Given that the rapid antigen tests rely on antibody detection of SARS-CoV-2 nucleocapsid (N),
319 even single amino acid mutations have the potential to impact test sensitivity. As such, test
320 performance should be re-assessed in light of new emerging variants of SARS-CoV-2, such as
321 B.1.1.7 that has become the dominant genotype in the UK and contains four mutations in N

322 compared to England 02/2020 (D3L, R203K, G204R and S235F).¹⁶ We performed small-scale
323 evaluations using matched swab samples spanning a range of Cts (12.7 to 31.8), from April
324 2020, September 2020, and confirmed (by viral sequencing) B.1.1.7-positive swabs from
325 January 2021 (**Figure 3**). Both Innova and SureScreen V tests showed variations in sensitivities
326 between the three batches of samples tested, as would be expected for biological samples, but
327 there was no evidence of altered sensitivity for the B.1.1.7 swabs.
328
329

330 Discussion

331

332 Through extensive head-to-head comparison, we found that most rapid antigen tests performed
333 to a high standard, with good sensitivity and excellent specificity. Consistent with previous
334 reports, the tests delivered an overall sensitivity of 65 to 89% in comparison with PCR,^{17–20}
335 rising to over 90% for most tests when compared with samples with Cts of 25 or less.^{18, 21,22}
336 Sensitivity levels increased to over 95% when compared with samples that were infectious *in*
337 *vitro*, with direct viral titre in the specimens correlating with Ct levels. This is the most
338 comprehensive comparison of antigen LFD and infectivity to date, demonstrating a clear
339 relationship between Ct values, quantitative culture of infectious virus and antigen LFD
340 positivity, with all tests delivering reliable identification of infectious clinical samples.

341

342 In agreement with previous studies, we cultured virus from upper respiratory tract specimens
343 with Cts of up to 26 (an equivalent viral load of 7×10^5 copies/mL),^{13,14,23} with the majority of
344 the culturable samples taken in the first week following symptom onset.^{12–14, 24} The minimum
345 viral titre required for transmission is unclear²⁴ and will depend in part on the proximity and
346 duration of contact. Nevertheless, it has been reported that higher viral loads, as measured by
347 lower Ct, are strongly associated with transmission⁹ and therefore reasonable to assume that
348 the quantity of cultured virus *in vitro* has a similar comparable correlation with infectivity.
349 There are, however, problems attempting to standardise Ct values as surrogate measures of
350 potential to transmit, due to differences in RNA extraction and RT-PCR methods. This is
351 demonstrated by a recent study in which differences of greater than 5 Cts between RT-PCR
352 systems prompted fears that rapid antigen LFDs were missing up to 50% of potentially
353 infectious cases.^{4–6} There have been frequent suggestions for SARS-CoV-2 results to be
354 presented as viral load (copies/mL) due to difficulties in comparing Ct values between studies.
355 However, the lack of an agreed standard for determining viral load is itself a problem, with
356 reported viral loads often appearing even more disparate than Cts.²⁵

357

358 While the reduced sensitivity of LFDs relative to PCR is less of a concern late in the infection
359 course when Cts are rising and the risk of onward transmission is negligible,⁹ it can be
360 problematic during the pre-symptomatic or early asymptomatic phase of infection.¹⁰ As
361 demonstrated by our longitudinal studies (**Figure 2D**), an individual can be positive by PCR
362 but negative by antigen test for one or two days before testing positive. A negative result
363 delivered at this stage in the course of infection could offer false security to someone who is
364 about to become highly infectious. Furthermore, with the time window of positive results
365 narrower than for PCR testing, relatively small differences in test sensitivities can translate to
366 capturing or missing potentially infectious cases. We therefore recommend that regular testing
367 be emphasised, and that tests are deployed in populations where the limitations of these tests
368 are understood and/or manageable.

369

370 In certain in-patient situations, LFDs can also be used to make early, rapid decisions about
371 patient management, with appropriate isolation pending confirmatory SARS-CoV-2 PCR
372 testing. This approach has recently been successful in hospital LFD pilot studies, with the use
373 of such devices preventing the cohorting of asymptomatic and/or infectious individuals with
374 uninfected patients while awaiting PCR results.²⁶ At the other end of the disease course, LFDs
375 could also be useful for determining if persistently PCR positive individuals pose a
376 transmission risk, potentially in tandem with rapid antibody testing.²⁷

377

378 Although the LFDs are very easy to use, the correct sampling, reading and interpretation of the
379 result are essential to their success in mass screening situations.¹ In particular, one must take

380 into account training and familiarity with swabbing when deploying devices to the general
381 public as compared with a trained healthcare worker in a hospital/clinic-based setting. It is
382 also easy to underestimate the importance of correctly recognising a positive band. We found
383 that some tests gave clearer results than other, as illustrated by the number of borderline results
384 seen in Figure 1 and 2. Removing this element of subjectivity, for example through the use of
385 an smartphone application to read/capture the LFD result, could improve success rates.

386
387 Our data support the judicious use of rapid antigen LFDs – not to replace PCR testing, but to
388 supplement the current testing capacity and rapidly identify infected individuals in situations
389 where they would otherwise go undetected. Although sensitivity is lower than PCR-based
390 testing, the rapid turnaround of these tests, their versatility in terms of cost and portability, and
391 their utility in disrupting transmission chains originating from infectious asymptomatic
392 individuals, outweighs the risk of missing positive cases.

393

394

395 Acknowledgments:

396 We thank the following sources for donation of test kits: the manufacturers of Spring,
397 SureScreen Fluorescent and SureScreen Visual, Encode, Innova and E25Bio.

398

399 We are extremely grateful to all patients and staff at St Thomas' Hospital who participated in
400 this study.

401

402

403 Contributors:

404 SP, RB, LS, BM, GN, SD, MHM, JDE, SJDN, RPG conceived the study and study design. SP,
405 RB, BM, LS, MTKI, TX, AM, RPG collated the data. LS, BM, TX, AM, GN, SD supervised
406 specimen collection. MJL and KJD generated reagents. SP and RPG analysed the data. SP,
407 SJDN, and RPG wrote the first draft of the manuscript. All authors critically reviewed the
408 manuscript. The corresponding author attests that all listed authors meet authorship criteria and
409 that no others meeting the criteria have been omitted.

410

411 Funding:

412 Research was supported by the Department of Health via a National Institute for Health
413 Research comprehensive Biomedical Research Centre award to Guy's and St. Thomas' NHS
414 Foundation Trust in partnership with King's College London and King's College Hospital
415 NHS Foundation Trust.

416

417 SP was supported by Huo Family Foundation Award and Wellcome Trust Senior Fellowship
418 (WT098049AIA) granted to SJDN.

419

420 King's Together Rapid COVID-19 Call awards to MHM, KJD, SJDN and RPG

421

422 Wellcome Trust Award (106223/Z/14/Z) to MHM

423

424 MRC Discovery Award MC/PC/15068 to SJDN, KJD and MHM

425

426 Huo Family Foundation Award to MHM, KJD and SJDN

427

428

429 Declaration of Interests

430 The authors state no conflicting interests.

431

432

433 Data Sharing

434 All relevant data are within the manuscript (and its supporting information files).

435

436

437

438 References

439

440 1 Crozier A. Put to the test: use of rapid testing technologies for Covid-19. *BMJ* 2021; 372:n208

441

442 2 Pavelka M, Van-Zandvoort K, Abbott S, et al. The effectiveness of population-wide, rapid
443 antigen based screening in reducing SARS-CoV-2 infection prevalence in Slovakia. *medRxiv*
444 doi: <https://doi.org/10.1101/2020.12.02.20240648>

445

446 3 Deeks J, Raffle A, Gill M. Covid-19: government must urgently rethink lateral flow test
447 roll out. *BMJ Opinion* (Jan 12, 2021). [https://blogs.bmj.com/bmj/2021/01/12/covid-19-
448 government-must-urgently-rethink-lateral-flow-test-roll-out](https://blogs.bmj.com/bmj/2021/01/12/covid-19-government-must-urgently-rethink-lateral-flow-test-roll-out)

449

450 4 Wise, J. Covid-19: Lateral flow tests miss over half of cases, Liverpool pilot data show.
451 *BMJ*. 2020;371:m4848.

452

453 5 Guglielmi G. Rapid coronavirus tests: a guide for the perplexed. *Nature*.
454 2021;590(7845):202-5.

455

456 6 Mina MJ, Peto TE, Garcia-Fiñan M, Semple MG, Buchan IE. Clarifying the evidence on
457 SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. *The Lancet*
458 [https://doi.org/10.1016/S0140-6736\(21\)00425-6](https://doi.org/10.1016/S0140-6736(21)00425-6)

459

460 7 He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of
461 Covid-19. *Nat Med*. 2020 May;26(5):672-675.

462

463 8 Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with
464 RT-PCR cycle threshold values in cases of Covid-19, England, January to May 2020. *Euro*
465 *Surveill*. 2020 Aug;25(32):2001483.

466

467 9 Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of Covid-19 in 282 clusters in
468 Catalonia, Spain: a cohort study. *Lancet Infect Dis*. 2021 Feb 2;S1473-3099(20)30985-3.
469 doi: 10.1016/S1473-3099(20)30985-3. Online ahead of print.

470

471 10 Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among
472 asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community
473 treatment center in the Republic of Korea. *JAMA Intern Med* 2020; 180:1447-52.

474

475 11 Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of
476 SARS-CoV-2. *BMJ* 2020; 371:m3862

477

478 12 Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic
479 samples. *Clin Infect Dis*. 2020; 71 (10): 2663-2666

480

481 13 Kim MC, Cui C, Shin K-R, et al. Duration of culturable SARS-CoV-2 in hospitalized
482 patients with Covid-19. *N Eng J Med*. 2021 Feb 18;384(7):671-673.

483

484 14 Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious
485 potential assessment - a systematic review. *Clinical Infectious Diseases* 2020, ciaa1764
486 <https://doi.org/10.1093/cid/ciaa1764>

487

- 488 15 Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing
489 antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat*
490 *Microbiol.* 2020 Dec;5(12):1598-1607.
491
- 492 16 Loconsole D, Sallustio A, Accogli M, et al. Genome sequence of a SARS-CoV-2 VUI
493 202012/01 strain identified from a patient returning from London, England, to the Apulia
494 region of Italy. *Microbiol Resour Announc.* 2021 10(4):e01487-20.
495
- 496 17 Drevinek P, Hurych J, Kepka Z, et al. The sensitivity of SARS-CoV-2 antigen tests in the
497 view of large-scale testing. *medRxiv* doi: <https://doi.org/10.1101/2020.11.23.20237198>
498
- 499 18 Peto T, et al. Covid-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: a
500 national systemic evaluation for mass-testing. *medRxiv* doi:
501 <https://doi.org/10.1101/2021.01.13.21249563>
502
- 503 19 Corman VM, Haage VC, Bleicker T, et al. Comparison of seven commercial SARS-CoV-
504 2 rapid point-of-care antigen tests. *medRxiv* doi:
505 <https://doi.org/10.1101/2020.11.12.20230292>
506
- 507 20 Jääskeläinen AE, Ahava MJ, Jokela P, et al. Evaluation of three rapid lateral flow antigen
508 detection tests for the diagnosis of SARS-CoV-2 infection. *medRxiv* doi:
509 <https://doi.org/10.1101/2020.12.30.20249057>
510
- 511 21 Kohmer N, Toptan T, Pallas C, et al. The comparative clinical performance of four SARS-
512 CoV-2 rapid antigen tests and their correlation to infectivity in vitro. *J Clin Med.* 2021;10(2).
513
- 514 22 Young S, Taylor SN, Cammarata CL, et al. Clinical Evaluation of BD Veritor SARS-CoV-
515 2 Point-of-CareTest Performance Compared to PCR-Based Testing and versus the Sofia 2
516 SARS Antigen Point-of-Care Test. *J Clin Microbiol.* 2020 59:e02338-20.
517
- 518 23 Wolfel R, Corman VM, Guggemos W, Seilmaier M, et al. Virological assessment of
519 hospitalized patients with Covid-19. *Nature.* 2020 May;581(7809):465-469.
520
- 521 24 Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV,
522 and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a
523 systematic review and meta-analysis. *Lancet Microbe.* 2021 Jan;2(1):e13-e22. doi:
524 [10.1016/S2666-5247\(20\)30172-5](https://doi.org/10.1016/S2666-5247(20)30172-5)
525
- 526 25 Han MS, Byun JH, Cho Y, et al. RT-PCR for SARS-CoV-2: quantitative versus
527 qualitative. *Lancet Infect Dis.* 2021 Feb;21(2):165.
528
- 529 26 Merrick B, Noronha M, Batra R, et al. Real-world SARS-CoV-2 lateral flow antigen
530 detection device deployment in the emergency department to optimise safe, accurate and
531 rapid diagnosis of Covid-19. Submitted
532
- 533 27 Agarwal V, Venkatakrisnan AJ, Puranik A, et al. Long-term SARS-CoV-2 RNA shedding
534 and its temporal association to IgG seropositivity. *Cell Death Discovery* 2020 6, 138.
535
536

537 Figure legends

538

539 **Figure 1**

540 **Comparative sensitivity of six commercial SARS-CoV-2 rapid antigen tests**

541

542 (A) Limits of detection were compared for six commercial SARS-CoV-2 rapid antigen tests
543 (Innova, Spring, E25 Bio, Encode, SureScreen visual (V) and SureScreen fluorescent (F)). 1-
544 10,000 PFU of Vero.E6-propagated SARS-CoV-2 (England 02/2020) were applied to each
545 test in triplicate (equating to 30-300,000 PFU/mL). For the purpose of comparison the results
546 are scored according to whether the test band was strongly positive (score = 2), unequivocally
547 positive (1), weakly positive (0.5) or negative (0), and presented as a heatmap. Equivalent Cts
548 are given in (B).

549

550 (B) Association between PFU/mL and threshold cycle (Ct) result for RT-PCR for the SARS-
551 CoV-2 *n* gene (N1 Ct). RNA was extracted from serial dilutions of Vero.E6-titred SARS-CoV-
552 2 (England 02/2020) and assayed by N1 RT-PCR. Error bars represent SD of three independent
553 experiments. Points were fitted with a semi-log regression, shown on the graph, with the
554 equation and the R^2 value given above the graph. Horizontal dashed red lines denote Ct values
555 of 25 and 28, the threshold cut-offs used for sensitivity determinations in (D).

556

557 (C) Association between RNA copy number and N1 Ct values. Copy number/mL was derived
558 from N1 RT-PCRs conducted on the Zeptometrix RNA standard. Points were fitted with a
559 semi-log regression, shown on the graph, with the equation of the line and the R^2 value given
560 above the graph. Horizontal dashed red lines denote Ct values of 25 and 28, the threshold cut-
561 offs used for sensitivity determinations in (D).

562

563 (D) Tests were evaluated in head-to-head comparisons on an identical panel of 100 SARS-
564 CoV-2-positive nasal/oropharyngeal swabs. Bars denote the N1 Ct result for each swab, shown
565 in ascending order, and the antigen test results for each sample are shown directly below each
566 bar. As for (A), antigen test results are presented as a heatmap. Sensitivity determinations from
567 this sample set are shown to the right of the heatmap for each test. Thresholds of Ct 25 and 28,
568 corresponding to 1.5×10^6 and 1.65×10^5 RNA copies/mL, or 400 and 50 PFU/mL, respectively,
569 are indicated on the figure as vertical green lines with corresponding sensitivity values for each
570 test at each threshold shown to the right of the heatmaps.

571

572 **Figure 2**

573 **Comparison of Ct value, infectivity and rapid antigen test result for 141 clinical samples** 574 **and four longitudinal examples**

575

576 (A) Infectivity, SARS-CoV-2 N1 Ct, and antigen test results for 3 commercial tests were
577 determined for 141 combined nasal/oropharyngeal swabs. Bars show the N1 Ct result for each
578 swab, shown in ascending order, and are individually coloured according to whether virus was
579 cultured from the sample. Black indicates successful virus isolation, white indicates no virus
580 growth, and grey undetermined. Antigen test results for each sample are shown directly below
581 each bar. As for Figure 1, results are scored according to whether the test band was strongly
582 positive (score = 2), unequivocally positive (1), weakly positive (0.5) or negative (0), and
583 presented as a heatmap; grey boxes indicate samples that were not tested on that particular test.
584 Sensitivity determinations from this sample set are shown to the right of the heatmap for each
585 test, showing overall sensitivity and sensitivity relative to infectious samples.

586

587 (B) Direct viral titres of swabs was determined by plaque assay and compared with N1 Ct
588 value.

589

590 (C) Ct results from (A) plotted against days post onset of symptoms for each sample. Points
591 are coloured according to whether virus growth was observed (red) or not (blue), left graph, or
592 whether the Innova antigen test was positive (red) or negative (blue), right graph.

593

594 (D) Longitudinal examples of infectivity, antigen test positivity, Ct and antibody detection.
595 Sequential combined nasal/oropharyngeal swab samples and matched serum samples were
596 obtained from four SARS-CoV-2-infected individuals. As for (A), bars show the N1 Ct value
597 for each sample, shaded according to whether samples were virus culture positive (black) or
598 negative (white). Antigen test results for each sample are shown below the bars. Antibody
599 detection in matched serum samples are shown in the bottom panels, with heatmaps
600 representing the magnitude of IgM and IgG detection in the SureScreen Covid-19 IgG/IgM
601 Rapid Test Cassette or the detection of neutralising antibodies to SARS-CoV-2 in an infectious
602 virus neutralisation assay on Vero.E6 cells.

603

604 **Figure 3**

605 **Comparative evaluation of antigen test sensitivity for the B.1.1.7 variant vs. England 02**

606

607 Combined nasal/oropharyngeal swabs were obtained from 23 individuals with confirmed
608 SARS-CoV-2/B.1.1.7 infection and compared with samples from before the variant was
609 widely circulating in the UK population - May and September 2020. All swabs were matched
610 for N1 Ct values, shown in ascending order in the bar graph, and tested on Innova and
611 SureScreen visual rapid antigen tests. The Ct 25 threshold, corresponding to 1.5×10^6 RNA
612 copies/mL or 400 PFU/mL, is indicated in green.

613

Table 2: Comparative specificity and sensitivity of six commercial SARS-CoV-2 rapid antigen tests

	SPECIFICITY				OVERALL SENSITIVITY				SENSITIVITY CT<25				SENSITIVITY CT<28			
	Total (N)	Negative	%	95% CI	Total (N)	Positive	%	95% CI	Total (N)	Positive	%	95% CI	Total (N)	Positive	%	95% CI
Innova	100	99	99.0	94.55-99.95	100	89	89.0	81.37-93.75	69	68	98.6	92.24-99.93	88	84	95.5	88.89-98.22
E25 Bio	100	86	86.0	77.86-91.47	100	75	75.0	65.70-82.45	69	65	94.2	86.02-97.72	88	73	83.0	73.76-89.39
SureScreen V	100	100	100.0	96.30-100.0	100	65	65.0	55.25-73.64	69	63	91.3	82.30-95.95	88	65	73.9	63.82-81.91
Spring	100	98	98.0	93.00-99.64	100	77	77.0	67.85-84.16	69	66	95.7	87.98-98.81	88	75	85.2	76.35-91.16
Encode	100	100	100.0	96.30-100.0	100	74	74.0	64.63-81.60	69	65	94.2	86.02-97.72	88	73	83.0	73.76-89.39
SureScreen F	100	98	98.0	93.00-99.64	100	69	69.0	59.37-77.22	69	61	88.4	78.75-94.01	88	66	75.0	65.04-82.87

Table 3: Sensitivity of three commercial SARS-CoV-2 rapid antigen tests compared with RT-PCR

	SENSITIVITY (cf. RT-PCR)											
	Overall				CT<25				CT<28			
	Total (N)	Positive	%	95% CI	Total (N)	Positive	%	95% CI	Total (N)	Positive	%	95% CI
SureScreen F	141	85	60.3	52.04-67.98	82	69	84.1	74.74-90.49	111	83	74.8	65.96-81.93
Innova	110	86	78.2	69.58-84.88	66	64	97.0	89.61-99.46	87	80	92.0	84.31-96.05
Encode	90	67	74.4	64.56-82.33	52	50	96.2	87.02-99.32	70	62	88.6	79.04-94.09

Table 4: Sensitivity of three commercial SARS-CoV-2 rapid antigen tests compared with Virus Isolation

	SENSITIVITY (cf. Virus Isolation)											
	Overall				CT<25				CT<28			
	Total (N)	Positive	%	95% CI	Total (N)	Positive	%	95% CI	Total (N)	Positive	%	95% CI
SureScreen F	57	54	94.7	85.63-98.57	54	52	96.3	87.46-99.34	57	54	94.7	85.63-98.57
Innova	46	45	97.8	88.66-99.89	43	42	97.7	87.94-99.88	46	45	97.8	88.66-99.89
Encode	34	34	100.0	89.85-100.0	32	32	100.0	89.28-100.0	34	34	100.0	89.85-100.0

Figure 1: Comparative sensitivity of six commercial SARS-CoV-2 rapid antigen tests






Figure 2: Infectivity head to head n=141


A



B



C



D




Figure 3: Comparative evaluation of antigen test sensitivity for the B.1.1.7 variant

